BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8435200)

  • 1. The effect of differing radiotherapeutic schedules on the response of glottic carcinoma of the larynx.
    Robertson AG; Robertson C; Boyle P; Symonds RP; Wheldon TE
    Eur J Cancer; 1993; 29A(4):501-10. PubMed ID: 8435200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of treatment time and smoking on local control and complications in T1 glottic cancer.
    van der Voet JC; Keus RB; Hart AA; Hilgers FJ; Bartelink H
    Int J Radiat Oncol Biol Phys; 1998 Sep; 42(2):247-55. PubMed ID: 9788401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma.
    Le QT; Fu KK; Kroll S; Ryu JK; Quivey JM; Meyler TS; Krieg RM; Phillips TL
    Int J Radiat Oncol Biol Phys; 1997 Aug; 39(1):115-26. PubMed ID: 9300746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypofractionated radiotherapy for T1N0M0 glottic cancer: retrospective analysis of two different cohorts of dose-fractionation schedules from a single institution.
    Laskar SG; Baijal G; Murthy V; Chilukuri S; Budrukkar A; Gupta T; Agarwal JP
    Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e180-6. PubMed ID: 22862908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation therapy in early glottic carcinoma: significance of prognostic factors and dose fractionation.
    Dinshaw KA; Sharma V
    Indian J Cancer; 1990 Sep; 27(3):143-53. PubMed ID: 2090566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling the optimal radiotherapy regime for the control of T2 laryngeal carcinoma using parameters derived from several datasets.
    Roberts SA; Hendry JH; Slevin NJ
    Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1173-82. PubMed ID: 9392560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimum overall times II: Extended modelling for head and neck radiotherapy.
    Fowler JF
    Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):113-26. PubMed ID: 18155893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperfractionated radiation in the treatment of squamous cell carcinomas of the head and neck: a comparison of two fractionation schedules.
    Garden AS; Morrison WH; Ang KK; Peters LJ
    Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):493-502. PubMed ID: 7852111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of increasing the treatment time beyond three weeks on the control of T2 and T3 laryngeal cancer using radiotherapy.
    Slevin NJ; Hendry JH; Roberts SA; Agren-Cronqvist A
    Radiother Oncol; 1992 Aug; 24(4):215-20. PubMed ID: 1410576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why to start the concomitant boost in accelerated radiotherapy for advanced laryngeal cancer in week 3.
    Terhaard CH; Kal HB; Hordijk GJ
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):62-9. PubMed ID: 15850903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation therapy in early carcinoma of the glottic larynx T1N0M0.
    Medini E; Medini A; Gapany M; Levitt SH
    Int J Radiat Oncol Biol Phys; 1996 Dec; 36(5):1211-3. PubMed ID: 8985045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term observations and salvage operations on patients with T2N0M0 squamous cell carcinoma of the glottic larynx treated with radiation therapy alone.
    Furusaka T; Matuda H; Saito T; Katsura Y; Ikeda M
    Acta Otolaryngol; 2012 May; 132(5):546-51. PubMed ID: 22264025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerated radiotherapy for T1 to T2 glottic cancer.
    Motegi A; Kawashima M; Arahira S; Zenda S; Toshima M; Onozawa M; Hayashi R; Akimoto T
    Head Neck; 2015 Apr; 37(4):579-84. PubMed ID: 24677592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose, time, and fraction size issues for late effects in head and neck cancers.
    Taylor JM; Mendenhall WM; Lavey RS
    Int J Radiat Oncol Biol Phys; 1992; 22(1):3-11. PubMed ID: 1727126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity of human squamous cell carcinoma of the larynx to fractionated radiotherapy.
    Rezvani M; Fowler JF; Hopewell JW; Alcock CJ
    Br J Radiol; 1993 Mar; 66(783):245-55. PubMed ID: 8472118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated radiotherapy for T1, 2 glottic carcinoma: analysis of results with KI-67 index.
    Sakata K; Oouchi A; Nagakura H; Akiba H; Tamakawa M; Koito K; Hareyama M; Asakura K; Satoh M; Ohtani S
    Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):81-8. PubMed ID: 10758308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-term results and cause of failure analysis in larynx cancer patients irradiated conventionally and with accelerated fractionation schedules in 1995-1998].
    Szutkowski Z; Kawecki A; Jarząbski A
    Otolaryngol Pol; 2014; 68(6):320-7. PubMed ID: 25441938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repopulation during radical radiotherapy for T1 glottic cancer.
    Saarilahti K; Kajanti M; Lehtonen H; Hämäläinen T; Joensuu H
    Radiother Oncol; 1998 May; 47(2):155-9. PubMed ID: 9683363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overall time in telecobalt therapy for T1 glottic carcinoma treated with 2 Gy per day.
    Inoue T; Inoue T; Teshima T; Murayama S; Yamazaki H; Nose T; Tanaka E
    Strahlenther Onkol; 1995 Aug; 171(8):475-7. PubMed ID: 7652672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour volume: implications in T2/T3 glottic/supraglottic squamous cell carcinoma.
    Lo SM; Venkatesan V; Matthews TW; Rogers J
    J Otolaryngol; 1998 Oct; 27(5):247-51. PubMed ID: 9800621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.